Cyproheptadine
- Generic Name
- Cyproheptadine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H21N
- CAS Number
- 129-03-3
- Unique Ingredient Identifier
- 2YHB6175DO
- Background
Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome.
- Indication
In the US, prescription cyproheptadine is indicated for the treatment of various allergic symptomatologies - including dermatographia, rhinitis, conjunctivitis, and urticaria - as well as adjunctive therapy in the management of anaphylaxis following treatment with epinephrine. In Canada, cyproheptadine is available over-the-counter and is indicated for the t...
- Associated Conditions
- Allergic Reactions caused by Transfusions, Anaphylaxis, Angioedema and urticaria, Cold urticaria, Conjunctivitis allergic caused by Food Allergy, Conjunctivitis allergic caused by inhalant allergens, Perennial Allergic Rhinitis (PAR), Pruritus, Seasonal Allergic Rhinitis, Serotonin Syndrome, Vasomotor Rhinitis, Dermatographism
- Associated Therapies
- Appetite stimulation
Pediatric Oncology Nutrition Intervention Trial
- First Posted Date
- 2023-12-18
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Corey Hawes
- Target Recruit Count
- 45
- Registration Number
- NCT06175273
- Locations
- 🇺🇸
University of Kentucky, Lexington, Kentucky, United States
Effect of Cyproheptadine on Ventilatory Support-free Days in Critically Ill Patients With COVID-19
- First Posted Date
- 2021-07-28
- Last Posted Date
- 2021-08-03
- Lead Sponsor
- Hospital de Clinicas de Porto Alegre
- Target Recruit Count
- 274
- Registration Number
- NCT04979221
- Locations
- 🇧🇷
Hospital de Clínica de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
- Conditions
- Interventions
- First Posted Date
- 2020-07-27
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- QuantumLeap Healthcare Collaborative
- Target Recruit Count
- 1500
- Registration Number
- NCT04488081
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸Sanford Health, Sioux Falls, South Dakota, United States
🇺🇸University of Rochester Medical Center, Rochester, New York, United States
Clinical Outcome of a Patented Pharmaceutical Composition (KT-110) to Treat Alcohol Use Disorder While Avoiding Major Side Effects
- First Posted Date
- 2019-09-27
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Kinnov Therapeutics
- Target Recruit Count
- 154
- Registration Number
- NCT04108104
- Locations
- 🇫🇷
Association Hospitalière de Bourgogne Franche-Comté, Saint-Rémy, France
🇫🇷Cabinet Médical, Bersée, France
🇫🇷HIA Clermont Tonnerre, Brest, France
Effects of Cyproheptadine on Growth and Behavior in Pediatric Feeding Disorders
- First Posted Date
- 2015-10-05
- Last Posted Date
- 2020-01-31
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 4
- Registration Number
- NCT02568007
Altering Activation Patterns Post-stroke
- Conditions
- Interventions
- First Posted Date
- 2015-04-17
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Shirley Ryan AbilityLab
- Target Recruit Count
- 96
- Registration Number
- NCT02418949
- Locations
- 🇺🇸
Rehabilitation Institute of Chicago, Chicago, Illinois, United States
A Study of Combination Therapy in Children With ADHD
- First Posted Date
- 2013-09-12
- Last Posted Date
- 2015-04-10
- Lead Sponsor
- Douglas Sears
- Target Recruit Count
- 99
- Registration Number
- NCT01940978
- Locations
- 🇺🇸
SMRI (Schuster Medical Research Institute), Van Nuys, California, United States
Mechanisms of Neuromuscular Fatigue Post Stroke
- Conditions
- Interventions
- First Posted Date
- 2012-09-20
- Last Posted Date
- 2015-11-05
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 27
- Registration Number
- NCT01688570
- Locations
- 🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
A Placebo-controlled Crossover Trial Using Cyproheptadine To Treat Children With Functional Abdominal Pain
- Conditions
- Interventions
- First Posted Date
- 2012-08-29
- Last Posted Date
- 2017-08-30
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 4
- Registration Number
- NCT01675050
- Locations
- 🇺🇸
UmichiganHS, Ann Arbor, Michigan, United States
Molecular Markers of Neuroplasticity During Exercise in People With Incomplete Spinal Cord Injury
- Conditions
- Interventions
- First Posted Date
- 2012-02-24
- Last Posted Date
- 2015-05-19
- Lead Sponsor
- T. George Hornby
- Target Recruit Count
- 30
- Registration Number
- NCT01538693
- Locations
- 🇺🇸
Rehabiliation Institute of Chicago, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.